antidiabetic drugs

systematic review meta-analysis network meta-analysis

Select diabetes type 2 All type of patientuncoded clinical condition ***       albiglutidebitherapy with METDPP-4 inhibitorsDPP-4 inhibitors add on current treatmentDPP-4 inhibitors add on insulinDPP-4 inhibitors add on METDPP-4 inhibitors add on MET+SUDPP-4 inhibitors add on SUDPP-4 inhibitors add on TZDDPP-4 inhibitors monotherapyglucagon-like peptide analogsinsulin therapylixisenatidemeglitinides (glinides)sulfonylureas G2sulfonylureas G2 add on METsulfonylureas G3 add on insulinsulfonylureas G3 add on METsulfonylureas G3 monotherapythiazolidinediones albiglutidealogliptindapagliflozinexenatideglimeripideglipizideglyburidelinagliptinliraglutidelixisenatide mitiglinidenateglinidepioglitazonerepaglinide rosiglitazonesaxagliptinsitagliptintaspoglutidevildagliptin vs add on insulinvs add on oral therapyvs placebovs placebo or controlvs standard glucose-lowering drugsvs SUvs active treatmentvs gliclazidevs insulinvs oral therapyvs Sulfonylureavs TZD      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (51)cardiovascular events (40)A CHANGER (36)vomiting (34)diarrhoea (33)Cardiovascular death (31)severe hypoglycemia (26)HbA1c (23)stroke (fatal and non fatal) (21)myocardial infarction (fatal and non fatal) (20)Adverse events leading to treatment discontinuation (20)macrovascular events (17)all hypoglycemia (11)serious adverse events (11)treatment-emergent adverse events (TEAEs) (11)Non fatal MI (10)severe adverse events (8)Fatal MI (7)Non fatal stroke (5)microvascular events (5)macrovascular or microvascular events (4)change in HbA1c (%) (3)all cause death, MI, stroke (3)Heart failure (3)Sudden death (2)vision loss (2)Amputations (2)change in body weight (kg) (1)change in daily mean glucose, mmol/L (1)change in FSG, mmol/L (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	cardiovascular events
diabetes type 2
albiglutide
Rosenstock (30 mg weekly), 2009      NCT	albiglutide weekly	placebo (add on MET)			Exploratory	suggesting
alogliptin
Nauck, 2009      NCT	alogliptin	placebo (add on MET)			Low risk of bias	negative
dapagliflozin
Bailey (MB102014), 2010          NCT	dapagliflozin	placebo (add on MET)			Low risk of bias	-
exenatide
Buse, 2011      NCT	exenatide 20µg/d	placebo (add on insulin)			Low risk of bias	negative
Fineman, 2003	exenatide other doses	placebo (add on MER+/-SU)			Exploratory	-
DeFronzo 10µg/d, 2005          NCT	exenatide 10µg/d	placebo (add on MET)			Low risk of bias	negative
DeFronzo 20µg/d, 2005      NCT	exenatide 20µg/d	placebo (add on MET)			Low risk of bias	suggesting
Kim, 2007      NCT	exenatide weekly	placebo (add on MET)			Exploratory	negative
Gao, 2009      NCT	exenatide 20µg/d	placebo (add on MET+/-SU)			Low risk of bias	suggesting
Buse 10µg/d, 2004          NCT	exenatide 10µg/d	placebo (add on SU)				negative
Buse 20µg/d, 2004	exenatide 20µg/d	placebo (add on SU)				-
Kadowaki (trial 8683), 2009	exenatide 10µg/d	placebo (add on SU+/-MET/TZD)			Exploratory	negative
Kendall 10µg/d, 2005      NCT	exenatide 10µg/d	placebo (add on SU+MET)			Low risk of bias	negative
Kendall 20µg/d, 2005      NCT	exenatide 20µg/d	placebo (add on SU+MET)			Low risk of bias	suggesting
Zinman 20µg/j, 2007    NCT	exenatide 20µg/d	placebo (add on TZD+/-MET)			Low risk of bias	suggesting
Zinman 20µg/j A MODIFIER, 2007	exenatide 20µg/d	placebo (add on TZD+/-MET)			Low risk of bias	-
phase 2 exenatide once monthly	exenatide once monthly	weekly exenatide				-
Exenatide Trial 10749	exenatide before lunch and dinner	exenatide before breakfast and dinner			Risk of bias	-
Heine, 2005	exenatide 20µg/d	insulin (add on SU+MET)				negative
Davis, 2007      NCT	exenatide 20µg/d	insulin (add on SU/MET)			Risk of bias	negative
Barnett, 2007      NCT	exenatide 20µg/d	insulin (add on SU/MET)			Exploratory	suggesting
Nauck, 2007      NCT	exenatide 20µg/d	insulin BIAsp twice daily add on SU+MET			Risk of bias	negative
DURATION-3 (Diamant), 2010    NCT	exenatide weekly	insulin glargine			Risk of bias	suggesting
Trial 8078	exenatide other doses	insulin glargine (add on MET/SU)				-
glimeripide
Study 201 (Goldberg), 1996	glimepiride	placebo			Low risk of bias	-
Schade, 1998	glimepiride	placebo			Low risk of bias	-
Rosenstock, 1996	glimepiride	placebo			Low risk of bias	-
Luis Bautista, 2003	glimepiride	placebo			Low risk of bias	-
Kaneko, 1993	glimepiride	placebo				-
Study 202	glimepiride	placebo				-
Riddle, 1994	glimepiride	placebo (add on insulin)				-
Charpentier, 2001	glimepiride	placebo (add on MET)			Low risk of bias	negative
Draeger, 1996	glimepiride	glibenclamide			Low risk of bias	-
Protocol 311	glimepiride	glibenclamide				-
Charpentier (301F)	glimepiride	gliclazide				-
Inukai, 2005	glimepiride	gliclazide or glibenclamide				-
Sonnenberg, 1997	glimepiride od	glimepiride bid				-
Clark (301), 1997	glimepiride	glipizide				-
Dills, 1996	glimepiride	glyburide			Low risk of bias	-
glipizide
Goldstein	glipizide	control (add on MET)				-
Rosenstock, 1993	glipizide	glyburide				-
Birkeland, 1994	glipizide	glyburide				-
Birkeland, 1994	glipizide	glyburide			Low risk of bias	-
Simonson, 1997	glipizide	placebo			Low risk of bias	-
Testa, 1998	glipizide	placebo				-
glyburide
Hermann, 1991	glibenclamide	c (add on MET)				-
DeFronzo, 1995	glyburide	c (add on MET)			Low risk of bias	-
Erle, 1999	glyburide	c (add on MET)				-
Marre (ass), 2002	glibenclamide	control (add on MET)			Low risk of bias	-
Tosi, 2003	glibenclamide	control (add on MET)			Low risk of bias	-
Blonde, 2002	glyburide	control (add on MET)			Low risk of bias	-
Garber, 2003	glyburide	control (add on MET)				-
Garber, 2002	glyburide	placebo			Low risk of bias	-
Vray, 1995	glyburide	placebo			Low risk of bias	-
linagliptin
Gallwitz, 2012      NCT	linagliptin	glimepiride (add on MET)			Low risk of bias	-
Owens      NCT	linagliptin	Metformin + sulfonylurea				-
Del Prato      NCT	linagliptin	placebo			Low risk of bias	-
Lewin, 2010    NCT	linagliptin	placebo (add on SU)			Low risk of bias	-
liraglutide
LEAD-2 (Nauck) (1.8mg vs placebo), 2009      NCT	liraglutide 1.8mg	placebo (add on MET)			Low risk of bias	suggesting
LEAD-1 SU (1.2 mg vs placebo), 2009        NCT	liraglutide 1.2mg	placebo (add on SU)			Low risk of bias	suggesting
LEAD-1 SU (1.8 mg vs placebo), 2009      NCT	liraglutide 1.8mg	placebo (add on SU)			Low risk of bias	suggesting
LEAD-5 (vs placebo), 2009      NCT	liraglutide 1.8mg	placebo (add on SU+MET)			Low risk of bias	suggesting
LEAD-4 (1.2mg), 2009      NCT	liraglutide 1.2mg	placebo (add on TZD+MET)			Low risk of bias	suggesting
LEAD-4 (1.8mg), 2009      NCT	liraglutide 1.8mg	placebo (add on TZD+MET)			Low risk of bias	suggesting
LEAD-6, 2009        NCT	liraglutide 1.8mg	exenatide on top MET/SU/MET+SU			Risk of bias	suggesting
Seino, 2010      NCT	liraglutide other doses	glibenclamide			Low risk of bias	negative
LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009      NCT	liraglutide 1.8mg	glimepiride (add on MET)			Low risk of bias	negative
LEAD-5 (vs Glargine), 2009    NCT	liraglutide 1.8mg	insulin glargine (add on SU+MET)			Risk of bias	negative
LEAD-1 SU (1.8 vs rosiglitazone), 2009      NCT	liraglutide other doses	rosiglitazone (add on SU)			Low risk of bias	suggesting
Pratley 1.2mg, 2010      NCT	liraglutide 1.2mg	sitagliptin			Risk of bias	suggesting
Pratley 1.8mg, 2010    NCT	liraglutide 1.8mg	sitagliptin			Low risk of bias	suggesting
lixisenatide
GETGOAL-L    NCT	lixisenatide	placebo (add on basal insulin)			Low risk of bias	-
Ratner DRI6012, 2010      NCT	lixisenatide	placebo (add on MET)			Exploratory	-
mitiglinide
Gao      NCT	mitiglinide	nateglinide			Low risk of bias	-
Kumashiro, 2007	mitiglinide	on top insulin glargine				-
Kaku, 2009	mitiglinide	placebo (on top pioglitazone)				-
nateglinide
Marre, 2002	nateglinide	placebo			Low risk of bias	-
Horton, 2000	nateglinide	placebo			Low risk of bias	-
Hanefeld, 1990	nateglinide	placebo			Low risk of bias	-
Saloranta, 2002	nateglinide	placebo			Low risk of bias	-
Mari, 2005	nateglinide	placebo				-
Moses, 2001	nateglinide	placebo			Low risk of bias	-
Goldberg, 1998	repaglinide	placebo			Low risk of bias	-
Jovanovic, 2000	repaglinide	placebo			Low risk of bias	-
Bech, 2003	repaglinide	placebo			Low risk of bias	-
Li, 2009	nateglinide	repaglinide				-
Li, 2007	nateglinide	repaglinide				-
Ristic, 2006	nateglinide	gliclazide (add on MET)			Low risk of bias	-
pioglitazone
PNFP-014	pioglitazone + insulin	placebo (add on insulin)			Exploratory	negative
OPI-502	pioglitazone + insulin	placebo (add on insulin)			Exploratory	negative
repaglinide
Moses, 1999	repaglinide	control (add on MET)			Exploratory	-
Landgraf, 1999	repaglinide	glibenclamide			Low risk of bias	-
Marbury, 1999	repaglinide	glibenclamide				-
Wolffenbuttel, 1999	repaglinide	glibenclamide			Low risk of bias	-
Madsbad, 2001	repaglinide	glipizide			Low risk of bias	-
Lund, 2007	repaglinide	metformin			Low risk of bias	-
Raskin, 2001	repaglinide	on top pioglitazone				-
Raskin, 2001	repaglinide	on top rosiglitazone				-
Raskin, 2000	repaglinide	on top troglitazone				-
Chuang, 1999	repaglinide	placebo				-
Goldberg, 1998	repaglinide	placebo			Exploratory	-
Jovanovic, 2000	repaglinide	placebo			Low risk of bias	-
Landin-Olsson, 1999	repaglinide	placebo (on top bedtime NPH-insulin)				-
rosiglitazone
SB-712753/009	rosiglitazone				Exploratory	-
49653/136	rosiglitazone	placebo			Exploratory	-
BRL 49653/347    NCT	rosiglitazone	placebo (add on insulin)			Exploratory	-
49653/085	rosiglitazone	placebo (add on insulin)			Exploratory	-
49653/095	rosiglitazone	placebo (add on insulin)			Exploratory	-
saxagliptin
saxgliptin, renal study	saxagliptin	placebo (add on current treatment)				-
CV181-057    NCT	saxagliptin	placebo (add on insulin)				-
DeFronzo, 2009      NCT	saxagliptin	placebo (add on MET)				negative
CV181-080    NCT	saxagliptin	placebo (add on MET)				-
Jadzinsky, 2009      NCT	saxagliptin	placebo (add on MET)				-
CV181-066    NCT	saxagliptin	placebo (add on MET)				-
Hollander      NCT	saxagliptin	placebo (add on TZD)				-
Rosenstock, 2008    NCT	saxagliptin	placebo (monotherapy)				-
CV181-011      NCT	saxagliptin	placebo (monotherapy)				-
CV181-038    NCT	saxagliptin	placebo (monotherapy)				-
CV181-041    NCT	saxagliptin	placebo (monotherapy)				-
saxagliptin vs sitagliptin	saxagliptin	sitagliptin (add on MET)				-
sitagliptin
Charbonnel, 2006      NCT	sitagliptin	placebo (add on MET)				negative
Nauck, 2007          NCT	sitagliptin	placebo (add on MET)				negative
Scott** (sit vs pbo on top met), 2007	sitagliptin	placebo (add on MET)				negative
Rosenstock (sit on top pio vs pbo), 2006      NCT	sitagliptin	placebo (on top PIO)				suggesting
Hermansen, 2007	sitagliptin	placebo (on-top glimepiride+/- metformine)				negative
taspoglutide
Nauck 10 once weekly vs PBO, 2009      NCT	taspoglutide 10mg once weekly	placebo			Exploratory	suggesting
Ratner (20mg once weekly), 2010      NCT	taspoglutide	placebo (add on MET)			Exploratory	suggesting
vildagliptin
Fonseca, 2007      NCT	vildagliptin	placebo (add on insulin)			Low risk of bias	suggesting
Ahren, 2004	vildagliptin	placebo (add on MET)			Low risk of bias	negative
Bosi, 2007      NCT	vildagliptin	placebo (add on MET)			Low risk of bias	negative
Goodman, 2009	vildagliptin	placebo (add on MET)			Low risk of bias	negative
Garber, 2007      NCT	vildagliptin	placebo (on top pioglitazone)				negative
Ferrannini, 2009      NCT	vildagliptin	Sulfonylurea (add on to MET)			Low risk of bias	suggesting
Bolli, 2008        NCT	vildagliptin	pioglitazone (add on MET)			Low risk of bias	negative
Rosenstock** (vilda + pio vs pio), 2007      NCT	vildagliptin	placebo (add on TZD)			Low risk of bias	negative